by Barry101 | Jun 14, 2023 | Press Release
Live webcast fireside chat on Wednesday, June 21st at 12:00 PM ETOCALA, Fla., June 14, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...
by Barry101 | Jun 12, 2023 | Press Release
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatment of pancreatic cancer (AMP-270) Ongoing progress toward...
by Barry101 | May 15, 2023 | Press Release
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023- Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter...
by Barry101 | May 9, 2023 | Press Release
OCALA, Fla., May 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Apr 12, 2023 | Press Release
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”),...
